Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses the treatment efficacy of pirtobrutinib in lymphoproliferative disorders, specifically Waldenström’s macroglobulinemia (WM), based on findings from the Phase I/II BRUIN trial (NCT03740529). Dr. Scarfò highlights the high activity and tolerability of pirtobrutinib treatment for WM, with low treatment discontinuation rates. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть